Genmab — Maj 2019

[Solsen]

Nordea skriver at det har noget med bivirkningerne at gøre. Altså at sc er bedre at give sammen med steroider, hvis jeg forstår rigtigt.

[Sukkeralf]

Ja nok mindre brug for steroider når mængden af infusionsreaktioner er væsentlig mindre ved sc end iv

[JohnW]

Ok, så det er korrekt forstået at vi taler om Dara SC imod solide tumorer?

[Bulder]

Undskyld solsen, ingen tanketorsk!. JnJ taler faktisk om at genoplive sc dara i solide.

[Sukkeralf]

Kunne de så ikke også lige komme ud over stepperne i RA ligeså

[E_L]

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). http://abstracts.asco.org/239/AbstView_239_247207.html

[E_L]

Bryan Garnier
"Isatuximab is not better than Darzalex

Detailed results of ICARIA-MM study to be presented at ASCO
Good results but not better than with Darzalex
Darzalex will benefit from the subcutaneous administration
We reduce our forecasts for isatuximab"

[Bulder]

Kunne være særdeles interessant med en dara-bcmaxcd3 duobody kombo. Ren in house.

[E_L]

the JNJ ASCO press release also mentions the Investigational Bispecific JNJ-61186372 (and offcourse Dara ) https://www.jnj.com/janssen-to-present-data-from-robust-oncology-portfolio-and-pipeline-at-the-2019-asco-annual-meeting-including-best-of-asco-selections

[Sukkeralf]

Mon ikke vi ser BCMA/CD3 data på ASH i år

[peter12]

EL link fails ...

[Doc4]

@peter12 EL link OK https://www.jnj.com/janssen-to-present-data-from-robust-oncology-portfolio-and-pipeline-at-the-2019-asco-annual-meeting-including-best-of-asco-selections

[Doc4]

Chatten digter på links i dag...se i browser adresselinjen og slet alt før www jnj

[Doc4]

Hmmm....ikke nemt det her 3w laves automatisk om til et link i chatten;(. Slet alt i adresselinjen før jnj's domæne navn (3w.jnj.com)

[E_L]

lets see if the link to yesterdays JNJ presentation works https://edge.media-server.com/m6/p/jjsewqjm

[E_L]

yes. ok, on the bottom in the right you can go directly to oncology if you want

[E_L]

maybe @gentogen can help find the slides of the presentation for download?

[E_L]

note, beyond 2023 growth area pre-malignent MM (smoldering)

[E_L]

mentioning JNJ 957 and 564 + SMM 'on the path way to a cure' for MM

[E_L]

Also mentioning JNJ 9178 in myeloid malignencies (CD123xCD3) which is also good news i guess, as we did not expect much anymore from that?